USC.edu
Are You a Patient?

Diana Lewez Hanna, MD

Assistant Professor of Clinical Medicine

Image of Diana Lewez Hanna, MD
Is this your profile? Click to edit
Email [email protected]
CTSI Profile

Overview

Dr. Hanna’s research interests include investigation of predictive and prognostic biomarkers in gastrointestinal malignancies and clinical trial protocol development with Dr. Heinz-Josef Lenz.

Dr. Hanna earned her medical degree from University of California, Davis. She then went on to complete her Hematology/Oncology Fellowship at USC, where she served as Chief Fellow.

Awards

  • Phi Sigma Honor Society, 2005
  • Phi Kappa Phi Honor Society, 2005
  • University of California, Davis: Professionalism of the Year in Internal Medicine Award, 2012
  • Division of Oncology, USC: Chief Fellow, 2014
     – 2015

Publications

  • HOPE Kids 2: Phase 3, Randomized Trial of Voxelotor in Children With SCD and Conditional Cerebral Blood Flow Velocities. Am J Hematol. 2026 Aug 28.. View in PubMed
  • Reply to “Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer”. Cancer. 2026 Jul 01; 132(13):e70510.. View in PubMed
  • Emerging precision therapeutics for pancreatic ductal adenocarcinoma: KRAS and beyond. Ther Adv Med Oncol. 2026; 18:17588359261432058.. View in PubMed
  • A Phase 1b Study of Botensilimab and Balstilimab in Treatment-Refractory Hepatocellular Carcinoma. Liver Cancer. 2026 Mar 30.. View in PubMed
  • A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer. Cancer. 2026 Mar 15; 132(6):e70343.. View in PubMed
  • Utility of Circulating Tumor DNA to Assess Tumor Response in Patients with Locally Advanced Rectal Cancer Undergoing Neoadjuvant Therapy. Cancers (Basel). 2026 Feb 11; 18(4).. View in PubMed
  • Outcomes of Patients With Solid Tumor Treated on Phase I Clinical Trials Within a Comprehensive Cancer Center’s Private and Safety-Net Hospitals. JCO Oncol Pract. 2025 Dec 03.. View in PubMed
  • Safety and efficacy of intratumourally administered INT230-6 in adult patients with advanced solid tumours: results from an open-label phase 1/2 dose escalation study. EBioMedicine. 2025 Nov; 121:105980.. View in PubMed
  • Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients with Resected Stages I-III Colon Cancer. Ann Surg. 2025 Aug 07.. View in PubMed
  • Targeting DNA helicase CMG complex and NFκB2-driven drug-resistant transcriptional axis to effectively treat KRASG12D-mutated pancreatic cancer. Exp Hematol Oncol. 2025 May 26; 14(1):79.. View in PubMed

Similar People